Generate Biomedicines Reports Q2 2026 Quarterly Results

What Happened
Generate Biomedicines, Inc. announced on August 6, 2026 that it issued a press release reporting its financial results for the quarter ended June 30, 2026. The press release is furnished as Exhibit 99.1 to the Form 8-K; the filing notes the furnished information is not being “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference in other filings unless expressly stated. The Form 8-K was signed by Jason Silvers, President and Chief Financial Officer.

Key Details

• Press release reporting quarterly results dated August 6, 2026 is attached as Exhibit 99.1.
• The results cover the quarter ended June 30, 2026 (the applicable quarterly reporting period).
• The company explicitly states the information is furnished—not filed—under the Exchange Act (limits certain liabilities and incorporation by reference).
• Form 8-K signed and dated August 6, 2026 by Jason Silvers (President & CFO).

Why It Matters
This filing tells investors that Generate has published its latest quarterly earnings and financial condition update; the full numbers and commentary are in the attached press release (Exhibit 99.1). Investors should review that press release for revenue, earnings (or loss), cash position, and any management commentary or guidance. This 8-K does not report other material events (e.g., executive changes, mergers) beyond the quarterly results disclosure.